RE:New Press Release - Theralase(R) Successfully Completes Non-GLP Toxicity Analysis for Brain CancerSince one of the big positives of TLT's treatment is Immuneogenic Cell Death (ICD) it would be great, but perhaps impossible now, to avoid test subjects who have had COVID19 or at least who've had it multiple times. It's now known that COVID causes dysfunction in the immune system (like HIV) and that immune response will be progressively weakened the more times a person has been infected. If TLT is counting on that immune response as part of the effectiveness of the treatment they may have to somehow take weakened immune systems into account.
https://libguides.mskcc.org/CovidImpacts/Immune